Share this article
Share this article
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the appointment of Matthew R. Patterson as Executive Chairman of the company s Board of Directors. Mr. Patterson is the co-founder and former chairman and CEO of Audentes Therapeutics, a gene therapy company acquired by Astellas Pharma in 2020. Matt has had an impressive 30-year career in research, drug development, and the commercialization of innovative therapeutics for both private and publicly held biotechnology companies, said Kevin Bitterman, PhD, Founding Chairman of the Board of Remix Therapeutics and Partner at Atlas Venture. His knowledge of the industry and experience building and advancing early-stage companies will be invaluable as we shape the path forward for Remix.